A 52-Week, Multicenter, Phase 1 Open-label Study to Evaluate the Safety of LX1001 in Participants with APOE4 Homozygote Alzheimers Disease

Clinical Trial Grant

Duke Scholars

Principal Investigator Kim G Johnson Psychiatry & Behavioral Sciences, Adult Psychiatry & Psychol ...

Administered By

School of Medicine

Awarded By

LEXEO Therapeutics, Inc

Start Date

October 21, 2022

End Date

May 1, 2024

Administered By

School of Medicine

Awarded By

LEXEO Therapeutics, Inc

Start Date

October 21, 2022

End Date

May 1, 2024